Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Emergent BioSolutions Restructures | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Emergent BioSolutions Restructures

Includes eliminating approximately 90 roles in an effort to improve overall cost structure and drive efficiencies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Emergent

Emergent BioSolutions, with its second quarter financial results, announced a restructuring initiative expected to result in annualized savings of approximately $40 million when fully implemented.

Efforts aim to improve overall cost structure, drive efficiencies and align resourcing needs of the organization; and includes eliminating approximately 90 roles.

According to the company, creation of a new growth organization aims to integrate R&D capabilities, business development, strategy into one function led by Stephanie Duatschek, Senior Vice President, Chief Global Strategy & Franchise Development Officer, who will assume the role of Executive Vice President, Chief Growth Officer, with responsibility for the Company’s strategic growth.

Revenue was $234.3 million in the second quarter, up 66%. The company reported a loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge.

Naloxone sales were down 22% in the quarter. Anthrax MCM sales were $12.3 million up 6%. Smallpox MCM sales were $101.6 million, up 150%. Other products accounted for $54.1 million, up from $6.2 million in 2Q25,which the company attributes to higher USG and international BAT® sales due to timing.

Revenues from Services increased $2.0 million, or 45%, as compared with 2Q25. The increase was primarily attributable to production activity at the Company’s Winnipeg facility.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics